NCT07877194Not yet recruitingPhase 2
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
A Phase II Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab in the Treatment of Advanced Renal Cancer
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
This study aims to evaluate the safety and efficacy of Ivonescimab alone or in combination with Cadonilimab or Ipilimumab in the treatment of advanced clear cell renal cell carcinoma (ccRCC).
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 29 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Apr 2029
- Lead sponsor
- Summit Therapeutics
- Diseases
- Kidney cancer
- NCT number
- NCT07877194
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 100
- From Oct 2026 to the primary completion date, Apr 2029
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous anti-tumor therapy toxicity has not been resolved.
- Have other malignancies within 5 years prior to enrollment.
Other illness
- Locally advanced disease that is resectable or suitable for local therapy with curative intent.
- Known presence of active pulmonary tuberculosis and active syphilis infection.
Other
- Histologically or cytologically confirmed renal non-clear cell carcinoma (nccRCC).
- Presence of active central nervous system (CNS) metastases.
- Other reasons for ineligibility as evaluated by investigator.
Who the study is looking for
- Able to understand and voluntarily sign a written informed consent form, which must be signed prior to the performance of the designated study procedures required by the study.
- Age ≥ 18 years both male and female.
- Karnofsky Performance Status Score (KPS) ≥ 70%.
- Expected survival ≥ 6 months.
- According to RECIST v1.1, there is at least one measurable lesion that is suitable for repeated and accurate measurements.
- Histologically or cytologically, pathologically confirmed renal cancer with a clear cell carcinoma component (ccRCC).
- Locally advanced or metastatic RCC not amenable to curative surgery or radiotherapy.
- Adequate organ function.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| - Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.